Search the Newsreel

Blue Nile’s New President Brings More Than 25 Years at Tiffany

Signet Jewelers (NYSE: SIG) has announced key leadership appointments for its brands, naming Jamie Cygielman as President of Zales and Banter, and Pam Cloud as President of Blue Nile. Cygielman, with 30 years of experience from Mattel and American Girl, will focus on Zales …

Signet Jewelers names new presidents for Zales and Blue Nile By Investing.com

Signet Jewelers has appointed Jamie Cygielman as President of Zales and Banter, and Pam Cloud as President of Blue Nile, as part of its strategy to strengthen its brand portfolio. Cygielman, previously from Mattel and American Girl, will oversee Zales and Banter's go-to-market strategies, …

Signet Jewelers Announces New Leadership for Zales, Banter and Blue Nile

Jamie Cygielman will lead Zales' next phase of growth and innovation, while Pam Cloud will lead Blue Nile's transformation as an elevated luxury brand, anchored in natural diamonds Appointments advance Signet's Grow Brand Love strategy to strengthen and differentiate its portfolio of brands HAMILTON, …

Steve Leung Design Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Insider Selling: Docusign (NASDAQ:DOCU) CFO Sells 15,000 Shares

Docusign's CFO, Blake Jeffrey Grayson, sold 15,000 shares of DOCU stock for $900,000 at an average price of $60 per share. This transaction, conducted under a Rule 10b5-1 plan, reduced his holdings by over 10%. Despite recent strong quarterly results exceeding analyst expectations, analysts …

Docusign price stalls - Forecast today - 11-08-2026

DocuSign (DOCU) experienced a slight downturn but maintains a bullish outlook as it consolidates recent gains. The stock is supported by an ascending trendline and its 50-day Simple Moving Average, indicating potential for further price increases. Analysts forecast a bullish trend, with the stock …

Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages

Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $16.50. The stock recently opened at $14.33, trading above its 50-day and 200-day moving averages, and institutional investors own over 56% of the …

Insight Digital Partners (DYOR) earns $2.7M but flags going concern risk

Insight Digital Partners II Q2 2026: Net income $1.4M, EPS $0.06— 10-Q Summary

Insight Digital Partners II reported net income of $1.4 million for Q2 2026, with diluted earnings per share of $0.06. For the first six months of 2026, consolidated net income was $2.66 million and diluted EPS was $0.12. The company's business focus is on …

Steve Leung Design Group narrows revenue dip but boosts interim profit

Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the first quarter, now holding 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of the company. Despite reporting a quarterly EPS of negative $0.32, beating …

The Ensign Group, Inc. (ENSG) Stock Analysis: Navigating a 20% Potential Upside Amid Strong Revenue Growth

The Ensign Group, Inc. (ENSG) presents a compelling investment opportunity with a potential upside of 20% due to strong revenue growth and positive analyst sentiment. Despite its stock being in overbought territory, the company demonstrates efficient management, profitability, and strategic expansion within the healthcare …

California State Teachers Retirement System Grows Holdings in Insight Enterprises, Inc. $NSIT

The California State Teachers Retirement System significantly increased its stake in Insight Enterprises (

Docusign Inc. $DOCU Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers reduced its stake in Docusign (NASDAQ:DOCU) by 31.8% in Q1 2026, selling 17,289 shares and retaining 37,108 shares worth $1.76 million. Despite institutional ownership of 77.64% and Docusign exceeding Q1 earnings expectations with $1.09 EPS and $830.24 million in revenue, analysts …

Assenagon Asset Management S.A. Buys 248,597 Shares of Docusign Inc. $DOCU

Assenagon Asset Management S.A. significantly increased its stake in Docusign Inc. by 247.5% in the second quarter, bringing its total holdings to 349,038 shares valued at approximately $15.5 million. This comes as Docusign exceeded quarterly earnings expectations, reporting $1.09 EPS on $830.24 million in …

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Price to earnings forward of Foresight Environmental Infrastructure Limited GBP – LSE:FGEN

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com

Sight Sciences (NASDAQ:SGHT) has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective Monday. Rashid brings extensive legal leadership experience from previous roles at Nevro Corp. and other companies. Concurrently, Jeremy Hayden will step down from the …

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

Sight Sciences, Inc. has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective immediately. Rashid brings extensive experience from previous legal leadership roles at several companies, and his compensation package includes an annual base salary of $450,000, …

VGNTw Price Today: Versigent PLC Stock Price, Quote & Chart | MEXC

This article provides the stock price, key market data, and company information for Versigent PLC (VGNTw), which designs and manufactures electrical architecture systems for vehicles and other industries. It details how to buy VGNTw on MEXC, its industry classification, and answers frequently asked questions …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Sight Sciences Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Sight Sciences Inc. for August 10, 2026. It is a brief, standard financial news update provided by Investing.com, indicating a regulatory filing has occurred for the company.

Cadence Design Systems Inc. stock underperforms Monday when compared to competitors

Cadence Design Systems Inc. (CDNS) stock fell 2.16% on Monday, underperforming the broader market. This drop occurred despite the S&P 500 Index and Dow Jones Industrial Average experiencing only slight declines. The stock's fall ended a two-day winning streak.

Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00

Stifel Nicolaus has reduced its price target for RxSight (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a "hold" rating, suggesting an 11.82% potential upside. Despite the lowered target, RxSight recently reported better-than-expected quarterly results, surpassing analyst estimates for both earnings per share and revenue. …

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

Insider at Company (NASDAQ: VRSN) files to sell 500 common shares

Thomas C. Indelicarto, an insider at VeriSign Inc. (NASDAQ: VRSN), has filed a Form 144 indicating a proposed sale of 500 shares of common stock with an approximate value of $146,175.00, to be sold on or after August 10, 2026. The filing also details …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

Keysight Technologies Inc. stock underperforms Monday when compared to competitors

Keysight Technologies Inc. (KEYS) shares dropped 1.63% on Monday, closing at $335.41. This underperformance occurred on a generally down day for the stock market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock's fall ended a two-day …

Can Rising Power Analyzer Demand Reshape Keysight Technologies’ (KEYS) Role in the Electrification Ecosystem?

Kaplan Fox Investigates The Ensign Group Over Alleged Securities Violations After Stock Drop

Kaplan Fox & Kilsheimer LLP has launched an investigation into The Ensign Group, Inc. (NASDAQ: ENSG) following a report by Hunterbrook Media alleging inadequate patient care and data misrepresentation. The Hunterbrook Media report, titled "Ensign: The Nursing Home Empire Built On Fatal Neglect," caused …

Insight Enterprises (NASDAQ:NSIT) Reaches New 1-Year High After Analyst Upgrade

Insight Enterprises (NASDAQ:NSIT) reached a new 52-week high after JPMorgan Chase & Co. raised its price target from $135 to $160, maintaining a neutral rating. The company reported strong quarterly earnings of $3.86 EPS on $2.40 billion in revenue, exceeding analyst estimates. Despite the …

Stifel cuts RxSight stock price target on competitive headwinds

Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) to $7.00 from $8.00 due to competitive headwinds, while maintaining a Hold rating. Despite the stock appearing undervalued and recent Q2 2026 earnings beating expectations, the company withdrew its full-year guidance. Stifel anticipates a turnaround …